Acute Kidney Injury in Surgical Patients — KDIGO Staging, Bundle Prevention, Fluids Discipline and Delayed RRT

Day-2 post-laparotomy, creatinine up from 88 to 152 micromol/L, urine 0.4 mL/kg/h for 8 hours, noradrenaline running, vancomycin trough-targeted, contrast CT yesterday. Is this stage 1 or 2, which drug do you change today, how much fluid does the kidney want, and when does the dialysis catheter go in? The examiner will watch you stage it without hesitation, defend the bundle from two randomised trials, refuse both fluid restriction and early dialysis with numbers, and book follow-up for a patient who feels fine. This page teaches each move with every number taken from the paper named beside it.^[1][19][38]

Definition & Staging — the three doors into AKI

AKI is defined by any one of three doors: creatinine up by at least 0.3 mg/dL (26.5 micromol/L) within 48 hours, creatinine to at least 1.5 times baseline within the prior 7 days, or urine below 0.5 mL/kg/h for 6 hours — the 2012 KDIGO international multidisciplinary guideline's single definition, built on evidence review with GRADE appraisal.^[1] Staging then runs: stage 1 is 1.5–1.9 times baseline or the 0.3 mg/dL rise with oliguria for 6–12 hours; stage 2 is 2.0–2.9 times baseline with oliguria for at least 12 hours; stage 3 is 3.0 times baseline or creatinine to 4.0 mg/dL (353.6 micromol/L) or dialysis started, with urine below 0.3 mL/kg/h for 24 hours or anuria for 12 hours.^[1] The standard definition deliberately fuses function (creatinine) with flow (urine), because either can declare injury first.^[5]

Time reframes the label. KDIGO calls AKI an abrupt fall over 7 days or less, chronic disease persistence beyond 90 days, and the ADQI consensus names the in-between — acute kidney disease, the course after AKI while pathophysiology continues — with its own staging and management strategies.^[3] For surgeons the clock matters twice: postoperative AKI is best defined as KDIGO AKI within 7 days of operation, with a focused kidney health assessment adding prognosis beyond the stage, and some form of follow-up assessment after discharge is essential rather than optional.^[4] The staging criteria themselves are validated in large cohorts and classify AKI into three stages — yet the American commentary cautions there is insufficient evidence to apply staging to routine clinical care, concurring otherwise with prevention and management while noting the continued absence of effective therapies beyond haemodynamic optimisation and nephrotoxin avoidance.^[14][2]

Epidemiology — how often, how deadly, in whose operation

Worldwide, 1 in 5 hospitalised adults and 1 in 3 children develop AKI, with AKI-associated mortality 23.9% in adults and 13.8% in children — mortality that falls as national income and health spending rise.^[8] In intensive care the burden concentrates: 57.3% of 1802 patients across 97 centres had AKI, with adjusted hospital-mortality odds of 1.68 for stage 1, 2.95 for stage 2 and 6.88 for stage 3 — and nearly half of AKI survivors (47.7% versus 14.8% without AKI) left hospital with eGFR below 60.^[7]

Surgery carries its own numbers. In a 400-patient surgical ICU cohort, 47.3% developed AKI — nearly 40% of it stage 3 — with higher BMI, APACHE-II, septic shock, ventilation, intercurrent complications and prior CKD as risk factors, and only stage 3 independently raising 28-day mortality (hazard ratio 7.75).^[9] After major non-cardiac surgery the headline is milder but longer: 6.8% sustained AKI (101 of 128 stage 1), yet in-hospital death ran 13.3% versus 0.9%, 1-year death 26.6% versus 6.1%, with an adjusted 1-year mortality hazard of 2.96 — and because creatinine falls during major illness, severity is underestimated and recovery overestimated.^[10] Even inside enhanced recovery, colorectal surgery produced 13.4% AKI (nearly all stage 1) with longer stay and six-fold major complications; preoperative creatinine, open (versus robotic, odds 0.15) surgery, each anaesthetic hour (odds 1.38) and major complications predicted it — balanced ERAS fluids kept severe AKI rare but did not abolish it.^[36] After cardiac surgery the median incidence is 27.75% across definitions, with definitional variation explaining the spread — and postoperative AKI raises long-term mortality (hazard ratio 1.68), halved when kidneys recover before discharge (1.31 versus 2.71 persistent).^[34]

Aetiology & Bedside Workup — perfusion, parenchyma, obstruction, then cause

AKI is a heterogeneous disorder, so when present the workup pursues cause with reversible causes first: prerenal perfusion failure (hypovolaemia, hypotension, low output, obstruction of flow before the kidney), intrinsic injury (tubular, interstitial, glomerular, vascular), and postrenal obstruction — more than one coexisting in the same patient.^[6] Surgery injures through all three at once, especially major and emergency procedures in the critically ill, layered onto chronic kidney and heart failure — while diuretics, contrast and nephrotoxic drugs commonly used perioperatively account for a significant share of hospital AKI.^[5] Short intraoperative hypotension already raises risk, so hypotension is avoided rather than tolerated — and intraoperative oliguria misleads in both directions, falling with intact kidneys and persisting with injured ones regardless of fluid responsiveness.^[5]

Two special differentials earn their own viva minutes. In cirrhosis, hepatorenal syndrome is extreme splanchnic-driven renal vasoconstriction where early diagnosis is central and newer definitions catch patients earlier — first-line is terlipressin with albumin, the only cure is liver transplantation, and the distinction from tubular necrosis is forced because vasoconstrictors are unjustified in ATN.^[45] In sepsis, AKI complicates most severe infections and vice versa: fluids and pressure maintenance prevent further damage, but mechanisms and best treatment remain unclear after multiple trials — so resuscitate the circulation by shock doctrine and judge the kidney by its own endpoints.^[46]

Risk Prediction — scores stratify, bundles prevent

Postoperative AKI prediction looks strong until examined. Across 42,615 noncardiac operations (10.1% AKI), gradient boosting lifted AUC from 0.712 on prehospital data to 0.804 preoperatively and 0.817 with intraoperative variables — yet the high-risk AKI rate moved only from 29.1% to 30.0%, a clinically trivial reclassification the authors themselves flag against the cost of intraoperative data plumbing.^[11] Independent validation is harsher: of nine published noncardiac models tested in 13,186 patients (4.9% AKI), only three reached fair discrimination (AUROC 0.71–0.75), the rest poor or failed, and all needed intercept-and-slope recalibration before any showed net benefit.^[12] After cardiac surgery a routine metabolic panel drawn a median 10 hours post-bypass predicts moderate-severe AKI at AUC 0.876 and dialysis-requiring AKI at 0.916 (validation 0.860) — excellent discrimination the authors still refuse to translate into practice without proof the tool improves outcomes.^[13]

The bedside risk list needs no model: older age, CKD, diabetes, heart failure, high BMI, high APACHE-II, septic shock, ventilation, open and long operations, intercurrent complications — each owned by the cohorts above, and each an indication to deploy the bundle rather than admire the score.^[4][9][36]

Biomarkers — damage signals before function falls

Creatinine and urine output are neither sensitive nor specific for early detection because they move only hours after injury — which is why cell-cycle-arrest markers matter: urinary TIMP-2 and IGFBP-7 are the best-performing early signals, with major surgery, cardiac surgery, instability and sepsis the priority populations for testing.^[15] The pair's product predicts AKI across intensive care, sepsis, cardiac surgery and emergency settings, and its clinical use is being tested in randomised intervention studies rather than assumed.^[14] After cardiovascular surgery the combination peaks early — best AUC at 2 hours after ICU admission, ahead of either marker alone, NGAL and L-FABP — so a negative early result reclassifies risk while creatinine still sleeps.^[16]

Trials use biomarkers as enrichment, not diagnosis. PrevAKI randomised only biomarker-positive cardiac patients ([TIMP-2]·[IGFBP7] above 0.3); ELAIN enriched with NGAL above 150 ng/mL at KDIGO stage 2; BigpAK-2 screened 7873 and randomised 1180 high-risk biomarker-positive major-surgery patients (15.0%).^[18][42][19] Enrichment rescues bundle trials from dilution — but a biomarker cannot stage, cannot name cause, and cannot order dialysis.^[15]

Prevention Bundles — the one intervention with two randomised wins

The bundle is four planks: optimise volume status and haemodynamics (with advanced or functional monitoring), avoid nephrotoxins and contrast, and prevent hyperglycaemia — the shared content of the PrevAKI and BigpAK-2 KDIGO strategies.^[18][19] PrevAKI proved it first in single-centre cardiac surgery: AKI 55.1% versus 71.7% (absolute reduction 16.6%, p=.004), moderate-severe disease also down, haemodynamics and glycaemia improved with less ACE-inhibitor/ARB use — but no other secondary moved, so it generates the hypothesis rather than closing the case.^[18] BigpAK-2 closed it across 34 European hospitals in high-risk major surgery: moderate-severe AKI 14.4% versus 22.3% (odds ratio 0.57, NNT 12, p=.0002) with no adverse-event difference — supportive measures plus avoidance, confirmed multicentre.^[19] Perioperative reviews agree that bundle implementation in high-risk patients reduced AKI occurrence — the "two studies" behind the current guideline advice.^[5]

European intensive-care doctrine frames the bundle with prohibitions. Titrate noradrenaline to MAP 65–70 (except chronic hypertension), resuscitate with crystalloids in controlled fashion, never overload — and the few strong high-evidence recommendations are all against: starches, low-dose dopamine, statins in cardiac surgery; with diuretics and levosimendan rejected for kidney protection outright.^[17] Crystalloids beat colloids for most patients, starches are avoided entirely, fluid balance is watched because overload in AKI predicts harm — and no targeted drug is approved for AKI treatment, so any 'renal-dose' prescription is examined as error.^[6]

Fluids & Haemodynamics — restriction injures, balance protects, pressure needs flow

RELIEF ended the restriction romance: 3000 high-risk abdominal operations randomised to 3.7 L versus 6.1 L perioperative fluid had identical disability-free survival but AKI 8.6% versus 5.0% (p < .001) with restriction, plus more surgical-site infection and more dialysis (0.9% versus 0.3%) — restriction trades kidneys for nothing.^[20] Observational practice confirms the mechanism from the other side: as crystalloid rates fell and vasopressor use rose across 26 hospitals, AKI rose with them — raising crystalloid from 1 to 10 mL/kg/h tracked a 58% lower AKI risk, and substituting pressors for volume to treat hypotension tracked more AKI, causality unproven but direction consistent.^[28] Both sides of pressure injure independently: each mmHg·day under MAP 65 (odds 1.55) and each µg/kg of cumulative noradrenaline (odds 1.02) predicted AKI in 38,338 noncardiac operations — so avoid profound hypotension AND high pressor doses, giving volume before squeezing vessels.^[27]

Fluid choice matters. Across 58 trials and 26,351 sepsis, surgical and trauma patients, balanced crystalloids and albumin brought better survival, less AKI and fewer transfusions than saline and low-molecular starch — balanced fluids cutting sepsis mortality versus saline (odds 0.84) and AKI versus starch (odds 0.80) — with the single reversal that brain injury favours saline over albumin and balanced fluids.^[21] Two 2025 negative trials complete the humility set: hypotension-prediction-index guidance changed nothing (moderate-severe AKI 6.1% versus 7.0%, RR 0.89, p=.66), and individualised nighttime-MAP targets lost to routine MAP ≥65 (composite 33.5% versus 30.5%, RR 1.10, p=.31) — technology and personalisation do not beat a simple pressure floor plus attention.^[25][26] On bypass, keeping oxygen delivery at or above 280 mL/min/m² halved mild AKI (RR 0.45) without touching severe grades — perfusion pressure with flow, not pressure alone.^[23]

The albumin paradox resolves by product. Iso-oncotic albumin as a resuscitation fluid beats saline and starch on survival and AKI in sepsis and surgery — but hyperoncotic 20% albumin infused after high-risk cardiac surgery INCREASED AKI (48.9% versus 43.4%, adjusted RR 1.12, worse with eGFR below 60), so routine hyperoncotic infusion is unsupported and the two albumins must never be merged in an answer.^[21][24]

Sepsis-Associated AKI — common, severe, bundle-responsive

Sepsis-associated AKI dominates ICU nephrology: among 5100 Korean ICU sepsis admissions, 62.3% developed SA-AKI and most of it was severe (58.0% stage 3) — with severe grades carrying the mortality signal.^[22] The actionable finding is bundle fidelity: adherence to the one-hour bundle's fluid resuscitation component nearly halved severe SA-AKI mortality (adjusted odds 0.62) — early fluids in sepsis save kidneys even as RELIEF warns against restriction in elective abdominal surgery, because undifferentiated shock and the prepared elective case are different physiologies.^[22][20] IDEAL-ICU then settles the dialysis question inside sepsis: early versus delayed RRT in septic shock with RIFLE-failure (creatinine tripled or ≥4 mg/dL with a rapid ≥0.5 rise, urine below 0.3 mL/kg/h for 24 hours, or anuria 12 hours) was stopped early for futility at 58% versus 54% mortality — with 38% of the delayed arm never dialysed.^[41]

Acidaemia gets its own honest negative. Bicarbonate infusion for severe acidaemia (pH ≤7.20) with moderate-severe AKI changed nothing on 90-day death (62.1% versus 61.7%) — though dialysis use fell (35% versus 50%): a threshold artefact or delayed trigger, not a survival signal, and candidates who call it a win fail the follow-up.^[29]

Contrast & Nephrotoxins — avoid first, mitigate second

Contrast injury in surgical patients is handled by avoidance inside the bundle — and where contrast is unavoidable, two meta-analyses bound the options. Furosemide with matched hydration through a closed-loop device cut contrast AKI (odds 0.31) and dialysis (odds 0.19) across 4 randomised trials in 698 coronary and valve patients — a device-dependent signal whose authors demand independent high-quality trials before doctrine.^[30] Across 147 trials and 33,463 cardiovascular-procedure patients, saline alone may not be optimal: vasodilator classes added to saline (including statins, prostaglandins and methylxanthines among others) carried the lowest contrast-AKI odds — signals to know, not standards to prescribe, with procedural detail fenced to radiology-for-surgeons.^[31]

Drugs deserve a daily review. AUC-guided vancomycin caused less AKI than trough-guided dosing (odds 0.625 across 10 studies and 4231 patients), supporting the 2020 shift to AUC monitoring at similar efficacy — so the trough-chasing surgeon is practising 2010 medicine.^[32] Prophylactic IV magnesium (median 2 g) with first-dose cisplatin tracked less kidney injury or death (2.7% versus 5.3%, adjusted odds 0.80) — observational, sensitivity-consistent, and explicitly awaiting randomised confirmation before it changes orders.^[33] And the bundle's third plank repeats daily: hold nephrotoxins and contrast where possible, hold ACE-inhibitors/ARBs perioperatively as PrevAKI did — because no rescue drug exists once injury lands.^[18][6]

RRT Timing — delay wins by avoidance, but know the floor

Three multinational trials and a Cochrane review now agree: without a mandatory trigger, waiting is safe and dialysing early harms. STARRT-AKI (2927 analysed, accelerated within 12 hours versus standard discouraged unless conventional indications or AKI beyond 72 hours) found 90-day death identical at 43.9% versus 43.7% — but early dialysis left more survivors dependent (10.4% versus 6.0%, RR 1.74) and caused more adverse events (23.0% versus 16.5%).^[38] AKIKI (620 severe KDIGO-3 patients) matched it at 60 days (48.5% versus 49.7%) while half the delayed arm (49%) never needed dialysis at all — at the price of doubled catheter bloodstream infections when started early (10% versus 5%).^[39] The delayed triggers to memorise: severe hyperkalaemia, metabolic acidosis, pulmonary oedema, BUN above 112 mg/dL, or oliguria beyond 72 hours — any one ends the wait.^[39] Cochrane's 12 trials and 4880 patients confirm: early kidney replacement changes death not at all (day-30 RR 0.97) while increasing hypophosphataemia, hypotension (RR 1.54), arrhythmia (1.35) and infection (1.33) — buying only ~2.5 fewer hospital days — and explicitly flags surgical AKI as the population future trials must study.^[43]

But delay has a floor, found by AKIKI-2: in 278 patients already past 72-hour oliguria or BUN 112 without a mandatory trigger, pushing further (waiting for BUN 140 or a crisis) gained no dialysis-free days (12 versus 10, p=.93) and raised 60-day death (hazard ratio 1.65) — longer postponement confers no benefit and potential harm.^[40] And ELAIN — the trial early-RRT enthusiasts quote — is the contradicted outlier: single-centre, 231 NGAL-enriched KDIGO-2 patients, mortality 39.3% versus 54.7% (HR 0.66) — outvoted by STARRT-AKI, AKIKI, IDEAL-ICU and Cochrane, its own authors calling for multicentre confirmation.^[42] The examined position: watch without a trigger, dialyse on any trigger, never push past the AKIKI-2 floor — and never cite ELAIN unqualified.^[38][40][42]

RRT Dose & Circuits — standard dose, citrate circuits

More dialysis is not better dialysis: 1124 critically ill patients randomised to intensive (6×-weekly dialysis, continuous therapy at 35 mL/kg/h) versus less-intensive (3×-weekly, 20 mL/kg/h) died identically by day 60 (53.6% versus 51.5%) with no recovery or organ-failure gain — so prescribe the standard dose and stop there.^[44] For continuous circuits, regional citrate beats unfractionated heparin: across 37 randomised trials and 2648 patients, citrate added 12.0 hours of filter life with less bleeding — the preferred anticoagulant, with single-trial exotic combinations too thin to adopt.^[37] Modality mechanics, access and citrate protocols belong to critical care; the surgeon owns three decisions — when (triggers above), how much (standard dose), and how anticoagulated (citrate first).^[44][37]

Special Populations — cardiac, elderly, cirrhotic, ERAS

Cardiac surgery concentrates every AKI lesson: median incidence 27.75%, goal-directed perfusion at DO2 ≥280 trimming only mild grades, biomarker bundles preventing (PrevAKI), hyperoncotic albumin harming (ALBICS) — assemble prevention from the bundle and perfusion, never from albumin infusion.^{[34][23][18][24]} The elderly valve patient gets the 48-hour rule: recovery within 48 hours carries non-AKI risk, persistence beyond predicts in-hospital and 1-year harm — so counsel by trajectory, not by peak creatinine.^[47] The cirrhotic surgical candidate forces the HRS-versus-ATN fork before any listing decision: terlipressin-plus-albumin for HRS, transplant as its only cure, and no vasoconstrictors for tubular necrosis.^[45] The emergency septic laparotomy with RIFLE-failure inherits IDEAL-ICU: safe to watch, with the five AKIKI triggers ending the wait the hour any appears.^[41][39]

Recovery & Follow-up — AKI is not self-limited

Even mild AKI shortens life for months to years, with milder forms still carrying excess morbidity and mortality — and growing evidence places AKI on the causal path to chronic kidney disease rather than as a mere risk marker.^[48] Recovery before discharge halves the long-term excess (cardiac hazard 1.31 versus 2.71 persistent), yet what counts as recovery short of dialysis-independence remains undefined — so follow-up is surveillance, not reassurance.^[34][48] Weaning and ceiling decisions use the CRRT predictors: rising urine output at discontinuation, lower SOFA and lower starting creatinine favour recovery; advancing age and sepsis favour death — translate each number into the bedside plan.^[35] The AKD window between injury and day 90 is owned by focused kidney health assessment — creatinine trajectory, proteinuria, pressure, nephrotoxin review — essential for every survivor, dictated in form by severity.^[3][4]

Evidence, Guidelines & Regional Differences — who proved what, where

KDIGO's 2012 international guideline defined and staged the disease; America's KDOQI commentary accepted the epidemiology use while withholding the clinical-care endorsement for lack of trial evidence; Europe's ESICM turned prevention into MAP targets and prohibition lists; and the ADQI/POQI perioperative consensus gave surgeons the 7-day definition plus lifelong follow-up language.^{[1][2][17][4]} The trial geography is French-led for timing (AKIKI, AKIKI-2, IDEAL-ICU, BICARICU-2), Canadian-led for scale (STARRT-AKI), German-led for bundles (PrevAKI, BigpAK-2, ELAIN) and Australian-led for fluids (RELIEF, ALBICS) — a genuinely global evidence base for a global examination.^{[39][38][19][20]}

Exam Pearls — the one-liners that score

• Stage by numbers, not gestalt: 0.3 mg/dL in 48 h, 1.5× in 7 days, or 0.5 mL/kg/h for 6 h — any one door admits.^[1]
• Postoperative AKI means KDIGO AKI within 7 days of the knife — plus a kidney health assessment and booked follow-up.^[4]
• The bundle prevents (BigpAK-2 NNT 12); the score only stratifies (best models AUROC ~0.75 after recalibration).^[19][12]
• Restriction injures (RELIEF 8.6 vs 5.0), balance protects (balanced over saline OR 0.84), overload harms — steer between all three.^[20][21][6]
• Delay dialysis without a trigger (STARRT identical mortality, half escape); never delay past the floor (AKIKI-2 HR 1.65); never cite ELAIN unqualified.^[38][40][42]
• Standard RRT dose, citrate circuits, no renal-dose dopamine/diuretics/levosimendan/statins — prohibitions score as highly as prescriptions.^[44][37][17]
• Mild AKI still kills at 1 year (aHR 2.96), creatinine dips lie, and 48-hour persistence resets prognosis — follow every survivor.^[10][47]

Revision summary

Creatinine ≥0.3 mg/dL/48 h, ≥1.5×/7 days, or urine below 0.5 mL/kg/h for 6 h defines AKI; stages run 1.5–1.9×, 2.0–2.9×, and 3.0×/4.0 mg/dL/dialysis with matching oliguria bands; PO-AKI is KDIGO AKI within 7 postoperative days. Prevent with the KDIGO bundle in biomarker-positive high-risk patients (BigpAK-2 OR 0.57, NNT 12); resuscitate with balanced crystalloids avoiding both restriction (RELIEF harm) and overload; keep MAP 65–70 and avoid pressor-for-volume substitution. Delay RRT without mandatory triggers (hyperkalaemia, acidosis, oedema, BUN >112, oliguria >72 h) per STARRT/AKIKI/Cochrane; never push past BUN 140 per AKIKI-2; standard RRT dose with citrate circuits. Follow every survivor with kidney health assessment — mild disease still predicts death and CKD.^{[1][19][20][38][40][10]}

References48ShowHide

1. [1]Kellum JA, et al. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care, 2013.PMID 23394211
2. [2]Palevsky PM, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury. Am J Kidney Dis, 2013.PMID 23499048
3. [3]Chawla LS, et al. Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup. Nat Rev Nephrol, 2017.PMID 28239173
4. [4]Prowle JR, et al. Postoperative acute kidney injury in adult non-cardiac surgery: joint consensus report of the Acute Disease Quality Initiative and PeriOperative Quality Initiative. Nat Rev Nephrol, 2021.PMID 33976395
5. [5]Zarbock A, et al. Update on Perioperative Acute Kidney Injury. Anesth Analg, 2018.PMID 30138176
6. [6]Moore PK, et al. Management of Acute Kidney Injury: Core Curriculum 2018. Am J Kidney Dis, 2018.PMID 29478864
7. [7]Hoste EA, et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med, 2015.PMID 26162677
8. [8]Susantitaphong P, et al. World incidence of AKI: a meta-analysis. Clin J Am Soc Nephrol, 2013.PMID 23744003
9. [9]Trongtrakul K, et al. Acute kidney injury in critically ill surgical patients: Epidemiology, risk factors and outcomes. Nephrology (Carlton), 2019.PMID 29124867
10. [10]O'Connor ME, et al. Acute kidney injury and mortality 1 year after major non-cardiac surgery. Br J Surg, 2017.PMID 28218392
11. [11]Lei VJ, et al. Risk Stratification for Postoperative Acute Kidney Injury in Major Noncardiac Surgery Using Preoperative and Intraoperative Data. JAMA Netw Open, 2019.PMID 31808922
12. [12]Zhuo XY, et al. Preoperative risk prediction models for acute kidney injury after noncardiac surgery: an independent external validation cohort study. Br J Anaesth, 2024.PMID 38527923
13. [13]Demirjian S, et al. Predictive Accuracy of a Perioperative Laboratory Test-Based Prediction Model for Moderate to Severe Acute Kidney Injury After Cardiac Surgery. JAMA, 2022.PMID 35258532
14. [14]Kimmel M, et al. Risk prediction of acute kidney injury by [TIMP-2]•[IGFBP7]. Drugs Today (Barc), 2017.PMID 28799580
15. [15]Nalesso F, et al. Evaluating Nephrocheck(®) as a Predictive Tool for Acute Kidney Injury. Int J Nephrol Renovasc Dis, 2020.PMID 32425580
16. [16]Iwata H, et al. Urinary [TIMP-2]•[IGFBP7], TIMP-2, IGFBP7, NGAL, and L-FABP for the prediction of acute kidney injury following cardiovascular surgery in Japanese patients. Clin Exp Nephrol, 2025.PMID 40195176
17. [17]Joannidis M, et al. Prevention of acute kidney injury and protection of renal function in the intensive care unit: update 2017 : Expert opinion of the Working Group on Prevention, AKI section, European Society of Intensive Care Medicine. Intensive Care Med, 2017.PMID 28577069
18. [18]Meersch M, et al. Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers: the PrevAKI randomized controlled trial. Intensive Care Med, 2017.PMID 28110412
19. [19]Zarbock A, et al. A preventive care strategy to reduce moderate or severe acute kidney injury after major surgery (BigpAK-2); a multinational, randomised clinical trial. Lancet, 2025.PMID 41242333
20. [20]Myles PS, et al. Restrictive versus Liberal Fluid Therapy for Major Abdominal Surgery. N Engl J Med, 2018.PMID 29742967
21. [21]Tseng CH, et al. Resuscitation fluid types in sepsis, surgical, and trauma patients: a systematic review and sequential network meta-analyses. Crit Care, 2020.PMID 33317590
22. [22]Song MJ, et al. Epidemiology of sepsis-associated acute kidney injury in critically ill patients: a multicenter, prospective, observational cohort study in South Korea. Crit Care, 2024.PMID 39581988
23. [23]Ranucci M, et al. Goal-directed perfusion to reduce acute kidney injury: A randomized trial. J Thorac Cardiovasc Surg, 2018.PMID 29778331
24. [24]Shehabi Y, et al. Postoperative 20% Albumin Infusion and Acute Kidney Injury in High-Risk Cardiac Surgery Patients: The ALBICS AKI Randomized Clinical Trial. JAMA Surg, 2025.PMID 40498523
25. [25]Ripollés-Melchor J, et al. Hemodynamic Management Guided by the Hypotension Prediction Index in Abdominal Surgery: A Multicenter Randomized Clinical Trial. Anesthesiology, 2025.PMID 39746186
26. [26]Saugel B, et al. Individualized Perioperative Blood Pressure Management in Patients Undergoing Major Abdominal Surgery: The IMPROVE-multi Randomized Clinical Trial. JAMA, 2025.PMID 41076588
27. [27]Saugel B, et al. Association of intraoperative hypotension and cumulative norepinephrine dose with postoperative acute kidney injury in patients having noncardiac surgery: a retrospective cohort analysis. Br J Anaesth, 2025.PMID 39672776
28. [28]Chiu C, et al. Fluids, vasopressors, and acute kidney injury after major abdominal surgery between 2015 and 2019: a multicentre retrospective analysis. Br J Anaesth, 2022.PMID 35688657
29. [29]Jung B, et al. Sodium Bicarbonate for Severe Metabolic Acidemia and Acute Kidney Injury: The BICARICU-2 Randomized Clinical Trial. JAMA, 2025.PMID 41159812
30. [30]Putzu A, et al. Prevention of Contrast-Induced Acute Kidney Injury by Furosemide With Matched Hydration in Patients Undergoing Interventional Procedures: A Systematic Review and Meta-Analysis of Randomized Trials. JACC Cardiovasc Interv, 2017.PMID 28231903
31. [31]Navarese EP, et al. Prevention of contrast-induced acute kidney injury in patients undergoing cardiovascular procedures-a systematic review and network meta-analysis. PLoS One, 2017.PMID 28151965
32. [32]Abdelmessih E, et al. Vancomycin area under the curve versus trough only guided dosing and the risk of acute kidney injury: Systematic review and meta-analysis. Pharmacotherapy, 2022.PMID 35869689
33. [33]Gupta S, et al. Intravenous Magnesium and Cisplatin-Associated Acute Kidney Injury. JAMA Oncol, 2025.PMID 40272825
34. [34]Corredor C, et al. Long-Term Consequences of Acute Kidney Injury After Cardiac Surgery: A Systematic Review and Meta-Analysis. J Cardiothorac Vasc Anesth, 2016.PMID 26482483
35. [35]Hansrivijit P, et al. A meta-analysis of clinical predictors for renal recovery and overall mortality in acute kidney injury requiring continuous renal replacement therapy. J Crit Care, 2020.PMID 32731101
36. [36]Drakeford PA, et al. Acute Kidney Injury within an Enhanced Recovery after Surgery (ERAS) Program for Colorectal Surgery. World J Surg, 2022.PMID 34665309
37. [37]Zhou Z, et al. Anticoagulation options for continuous renal replacement therapy in critically ill patients: a systematic review and network meta-analysis of randomized controlled trials. Crit Care, 2023.PMID 37287084
38. [38]Bagshaw SM, Wald R, Adhikari NKJ, et al. Timing of Initiation of Renal-Replacement Therapy in Acute Kidney Injury. N Engl J Med, 2020.PMID 32668114
39. [39]Gaudry S, et al. Initiation Strategies for Renal-Replacement Therapy in the Intensive Care Unit. N Engl J Med, 2016.PMID 27181456
40. [40]Gaudry S, et al. Comparison of two delayed strategies for renal replacement therapy initiation for severe acute kidney injury (AKIKI 2): a multicentre, open-label, randomised, controlled trial. Lancet, 2021.PMID 33812488
41. [41]Barbar SD, et al. Timing of Renal-Replacement Therapy in Patients with Acute Kidney Injury and Sepsis. N Engl J Med, 2018.PMID 30304656
42. [42]Zarbock A, et al. Effect of Early vs Delayed Initiation of Renal Replacement Therapy on Mortality in Critically Ill Patients With Acute Kidney Injury: The ELAIN Randomized Clinical Trial. JAMA, 2016.PMID 27209269
43. [43]Fayad AI, et al. Timing of kidney replacement therapy initiation for acute kidney injury. Cochrane Database Syst Rev, 2022.PMID 36416787
44. [44]Palevsky PM, Zhang JH, O'Connor TZ, et al. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med, 2008.PMID 18492867
45. [45]Francoz C, et al. Hepatorenal Syndrome. Clin J Am Soc Nephrol, 2019.PMID 30996046
46. [46]Skube SJ, et al. Acute Kidney Injury and Sepsis. Surg Infect (Larchmt), 2018.PMID 29304308
47. [47]Lin YW, et al. Early Acute Kidney Injury Recovery in Elderly Patients Undergoing Valve Replacement Surgery. J Cardiothorac Vasc Anesth, 2024.PMID 39019743
48. [48]Patel SS, et al. Sequelae of AKI. Best Pract Res Clin Anaesthesiol, 2017.PMID 29248147